marked.bio

KRAS G12C inhibitor (ON/OFF) · small molecule

olomorasib

4 active trials, targeting KRAS G12C. Not approved for any biomarker on marked.bio yet.

Also known as LY3537982.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
KRAS G12C 4 6 Phase 3

Sponsors

Industry sponsors leading active biomarker-selected trials of olomorasib.

  1. Eli Lilly 4

Trials

4 of 6 trials shown

  1. Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

    Recruiting Phase 3 Eli Lilly Started 2025Primary completion 2029-05 NCT06890598

    olomorasibpembrolizumabdurvalumab

    Must have disease with evidence of KRAS G12C mutation.

    KRAS G12CCarcinoma, Non-Small-Cell Lung

  2. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

    Recruiting Phase 3 Eli Lilly Started 2023Primary completion 2027-11 NCT06119581

    olomorasibpembrolizumabcisplatincarboplatinpemetrexed

    Must have disease with evidence of KRAS G12C mutation.

    KRAS G12CCarcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

  3. A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation

    Not yet recruiting Phase 2 Eli Lilly Started 2026Primary completion 2028-11 NCT07814417

    olomorasibcetuximaboxaliplatinleucovorinfluorouracil

    Must have disease with evidence of KRAS G12C mutation

    KRAS G12CColorectal Neoplasms

  4. Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

    Active, not recruiting Phase 1/2 Eli Lilly Started 2021Primary completion 2027-04 NCT04956640

    olomorasibpembrolizumabcetuximabpemetrexedcisplatincarboplatin

    Patients must have disease with evidence of KRAS G12C mutation in tumor tissue or circulating tumor deoxyribonucleic acid (DNA).

    KRAS G12CCarcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms, Ovarian Neoplasms